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ABSTRACT 
Abstract title: Molecular Characterization of a Novel Mucopolysaccharidosis (MPS) type VI-causing 
Mutation – Indirect Proof of Principle on its Pathogenicity 
Authors, Author affiliations, e-mail of presenting author: Coutinho MF1*, Encarnação M2*, Santos 
JI1, Matos L1, Alves S1 1 Research and Development Unit, Department of Human Genetics, INSA, 
Porto, Portugal; 2 Newborn Screening, Metabolism and Genetics Unit, Department of Human Genetics, 
INSA, Porto, Portugal *These authors contributed equally to the work Presenting author e-mail: 
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Text body: Introduction: With its unprecedented throughput, scalability and speed, next-generation 
sequencing (NGS) is revolutionizing clinical research. Targeted sequencing in particular is now available 
in many labs. Still, whenever a novel variant is detected, its pathogenicity must be carefully assessed and 
every now and again, a case pops up to highlight how tricky and delicate this process can be. Here we 
present a case of a molecular diagnosis of a patient with a clinical suspicion of MPS type VI, where even 
though the causal mutation was easy to detect by both Sanger and NGS, only through indirect studies 
could we present proof of principle on its pathogenicity. Methods: Initial studies were performed in 
gDNA, by classical sequencing of the ARSB gene, encoding arylsulfatase B, the enzyme deficient in 
MPS VI. Additional analyses included segregation studies, cDNA sequencing and NGS with in a custom 
gene for Lysosomal Storage Diseases (LSD) that includes 86 genes implicated in lysosomal function. 
Results and Discussion: After both Sanger and NGS, the novel c.1213+5G>T ARSB homozygous 
mutation was detected as the most probable cause for disease, with several bioinformatic predictors 
supporting its pathogenecity and segregation studies confirming its presence in heretozygozity in both 
parents. Still, we only had access to an extremely degraded cDNA sample obtained from blood of one of 
his parents and after ARSB amplification, its splicing pattern observed was surprisingly normal. We then 
conducted a classical sequencing approach of the ARSB gDNA and cDNA on the proband’s father and 
ended up demonstrating that, while being heterozygous for a SNP in the surroundings of the mutation, the 
same individual seemed wild-type homozygous for that exact same SNP at cDNA level. This observation 
provided indirect proof of the mutation’s effect on splicing, suggesting that the mutant transcript is 
degraded by nonsense-mediated mRNA decay (NMD). We are currently performing in vitro analysis 
using a minigene assay to further confirm its pathogenic mechanism. Overall, this case reminds us that, 
whatever the technology we use, genetic testing still needs much perseverance and cunning strategies to 
identify the causative mutation(s). Acknowledgements This work was partially supported by Fundação 
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